Relationship between weight loss during IMRT and outcomes in patients with head and neck cancer
PO-1112
Abstract
Relationship between weight loss during IMRT and outcomes in patients with head and neck cancer
Authors: Kenji Makita1,2, Yasushi Hamamoto2, Hiromitsu Kanzaki2, Kei Nagasaki2, Teruhito Kido1
1Ehime University Graduate School of Medicine, Department of Radiology, Toon, Ehime, Japan; 2National Hospital Organization Shikoku Cancer Center, Department of Radiation Oncology, Matsuyama, Ehime, Japan
Show Affiliations
Hide Affiliations
Purpose or Objective
Weight loss (WL) is often observed during radiotherapy for head and neck squamous carcinoma (HNSCC). Because there is controversy whether WL during radiotherapy for HNSCC affects the treatment outcomes, relationship between WL during radiotherapy and treatment outcomes was examined.
Material and Methods
Between January 2011 and December 2020, 85 patients with HNSCC (nasopharynx, 28; oropharynx, 22; hypopharynx, 28; larynx, 7) received intensity-modulated radiation therapy (IMRT) of 66-70 Gy (median, 70 Gy), and were weighted at the start and every week of IMRT treatment. Concurrent chemo/biotherapy was performed in 71 patients.
Results
Median follow-up time was 29.4 months (range, 4.4-110.5 months). Median WL and percent of WL were 4.8 kg (range, 0-13.3 kg) and 8.4% (range, 0-18.2%), respectively. Three-year overall survival rates, progression-free survival rates (PFS), and locoregional control rates (LC) were 91%, 72%, and 86%, respectively. There were no statistically significant differences in PFS (HR 1.014; 95%CI 0.371-2.773; p=0.978) and LC (HR 0.427; 95%CI 0.120-1.518; p=0.1884) in patients with or without moderate (5%) WL. In addition, there were also no statistically significant differences in PFS (HR 0.568; 95%CI 0.222-1.455; p=0.239) and LC (HR 0.169; 95%CI 0.021-1.338; p=0.092) in patients with or without severe (10%) WL.
Conclusion
Clear relationship between WL during IMRT for HNSCC and treatment outcomes could not be found.